In breast cancer, DCs purified from cancer patients have a decreased ability to stimulate T cells [78], and tumor-infiltrating DCs suppress the function of CD8+ T cells via TGF-β, NO, IL-10, VEGF, and arginase I [78]. Here, IL10 is linked to neoplasm.